Navigation Links
Repligen Receives Research Grants to Support Friedreich's Ataxia Development Program
Date:9/4/2008

imately one in every 50,000 people in the United States has Friedreich's ataxia. There is currently no treatment or cure for Friedreich's ataxia.

About the Muscular Dystrophy Association

The Muscular Dystrophy Association is a voluntary health agency working to defeat more than 40 diseases through programs of worldwide research, comprehensive services, and far-reaching professional and public health education. Friedreich's ataxia is one of the diseases covered by MDA. For more information, go to http://www.mda.org.

About the Friedreich's Ataxia Research Foundation

The Friedreich's Ataxia Research Foundation is a national, public, non- profit, tax-exempt organization dedicated to the pursuit of scientific research leading to treatments and a cure for Friedreich's ataxia. FARA's mission is to slow, stop, and reverse the damage caused by this disorder. For more information, go to http://www.curefa.org.

About the National Ataxia Foundation

The National Ataxia Foundation is a membership supported, non-profit organization established in 1957 to help persons with ataxia and their families. The Foundation's primary purpose is to support promising ataxia research and to provide vital programs and services for ataxia families. For more information, go to http://www.ataxia.org.

About Repligen Corporation

Repligen Corporation is a biopharmaceutical company focused on the development of novel therapeutics for neurological disorders. In addition, we are the world's leading supplier of recombinant Protein A, the sales of which partially fund the advancement of our development pipeline while supporting our financial stability. Repligen's corporate headquarters are located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453. Additional information may be requested from '/>"/>

SOURCE Repligen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
2. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
3. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
4. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
5. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
6. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
7. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
8. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
9. IsoTis Receives FDA Clearance for Accell Family of Products
10. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
11. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014  Decision Resources ... Brazil and Mexico ... uptake of several newly approved agents, the anticipated ... indication and the launch of emerging biologics will ... In particular, the emerging IL-5 inhibitors will introduce ...
(Date:8/21/2014)... , Aug. 21, 2014  China Cord Blood Corporation (NYSE: ... plan to release financial results for the first quarter ... after market close in the US.  ... a.m. ET on Friday, August 29, 2014 to discuss ... the Company,s recent developments, followed by a question and ...
(Date:8/21/2014)... Ontotext S4 , The Self Service Semantic ... Now the same enterprise hardened text mining, Linked Data ... is available to start-ups and mid-size businesses at a ... do not have resources to evaluate and prototype enterprise ... there is no need for on premise hardware provisioning ...
(Date:8/21/2014)... Wednesday of last week RENU 28, the world's first and ... for purchase in Australia and New Zealand, and the response ... is, if you think about the definition of aging, it's ... within your body. If you think about the definition of ... What RENU 28 does is it works with these tiny ...
Breaking Biology Technology:Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4RENU 28 Skin Care Now Available in Australia and New Zealand 2
... this sudden accident incubates a branding process, which can result ... birth to an extreme name identity, whereupon a major advertising ... stirred -- and that's how we refer to today's trendy ... secrets of the various branding tricks and become aware of ...
... met last week, we reviewed the performance of the Midwest large cap ... stock market indices reacted during the first half of 2005. , ,The ... can be seen below) with the exception of the Amex Biotech index. ... were up on a very solid basis. , , , ...
... Although outsourcing has been utilized by thousands of U.S. ... controversial topic. In fact, lawmakers in more than 35 ... popularity among corporations as an effective cost-cutting tool has ... not usually mean offshore outsourcing, it was ...
Cached Biology Technology:Accidental naming 2Accidental naming 3Accidental naming 4Midwest biotech stocks receive hefty haircut in first half of 2005 2Consider the legal issues before outsourcing offshore 2Consider the legal issues before outsourcing offshore 3Consider the legal issues before outsourcing offshore 4Consider the legal issues before outsourcing offshore 5
(Date:8/22/2014)... discoveries in basic and clinical research and technological ... a complex offensive spanning multiple fronts. , Work ... could help find new and more selective therapies ... targets a specific enzyme overexpressed in certain cancersand ... brain tumours. , Chemistry professor Christopher Cairo and ...
(Date:8/22/2014)... strong antioxidants and can reduce free radical ... against oxidative stress? Jianbo Zhao and co-workers ... Medical University, China discovered that green tea ... neuronal apoptosis, indicating green tea polyphenols play ... under oxidative stress. The relevant study has ...
(Date:8/22/2014)... Stanford, CAEveryone,s heard of the birds and the ... flowers that are being fertilized. The fertilization process ... extensive communication between the male and female reproductive ... Stanford, Regensburg, Heidelberg, and Munich, and including Carnegie,s ... discoveries in the chemical signaling process that guides ...
Breaking Biology News(10 mins):New enzyme targets for selective cancer therapies 2New enzyme targets for selective cancer therapies 3Calcium and reproduction go together 2
... States and Europe has identified more than a dozen genes ... forms of kidney disease. The team, known as the CKDGen ... 65,000 individuals of European descent. Common variations in several genes ... kidney function or chronic kidney disease than in those with ...
... artificial light at night disrupts circadian cell division, reveals ... of the University of Haifa-Oranim Department of Environmental and ... the University of Leicester. "Damage to cell division is ... understand the causes of this damage," notes Dr. Ben-Shlomo. ...
... HEIDELBERG, Germany, 12 April 2010 More than 120 leading ... EMBO Meeting 2010 the second annual life sciences conference ... held in Barcelona from 4 - 7 September 2010. ... Elizabeth Blackburn Roles of telomeres & telemorase in health ...
Cached Biology News:International research team discovers novel genes influencing kidney disease risk 2Call for abstracts and registration the EMBO Meeting 2010 2Call for abstracts and registration the EMBO Meeting 2010 3
Rabbit polyclonal to Retinoic Acid Receptor beta 2 ( Abpromise for all tested applications). entrezGeneID: 5915...
Ca2+ Channel Ca gamma 2 Purified Anti-Mouse, Anti-Rat, Anti-Human clone Polyclonal, Isotype Rabbit Ig, 50 µl Consult technical datasheet for details....
...
... for spontaneous ligand immobilization can be coupled with ... or receptor to create an affinity matrix of ... ligands via primary amines. Affi-Gel 10 gel couples ... to 11; Affi-Gel 15 gel couples acidic proteins ...
Biology Products: